Cadila Healthcare today said its group firm Zydus Cadila has received final approval from the US health regulator for its generic version of Tizanidine tablets used for treatment of muscle spasms.
The approval by the US Food and Drug Adminstration (USFDA) is for multiple strengths of 2 mg and 4 mg, the company said in a BSE filing.
The tablets will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, the company added.
The group has more than 180 approvals with over 320 abbreviated new drug approvals (ANDAs) filed since 2003-04, the company said.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)